Review article · 2016 · Open access

Targeting Inflammation in Cancer Prevention and Therapy

Jelena Todoric, Laura Antonucci, Michael Karin

Cancer Prevention Research, 9(12), 895–905 · Published 11 November 2016 · DOI 10.1158/1940-6207.capr-16-0209

Read the free full textView at the publisherCite this paper

In brief

“Targeting Inflammation in Cancer Prevention and Therapy” is a 2016 review article by Jelena Todoric and 2 co-authors, published in Cancer Prevention Research. OpenAlex counts 382 citations as of 15 November 2026. It is open access: the full text is free to read at PubMed Central.

Citations
382
Most cited in
2020 (57)
Field-weighted impact
3.66
References
150
Authors
3

Abstract

Inflammation is associated with the development and malignant progression of most cancers. As most of the cell types involved in cancer-associated inflammation are genetically stable and thus are not subjected to rapid emergence of drug resistance, the targeting of inflammation represents an attractive strategy both for cancer prevention and for cancer therapy. Tumor-extrinsic inflammation is caused by many factors, including bacterial and viral infections, autoimmune diseases, obesity, tobacco smoking, asbestos exposure, and excessive alcohol consumption, all of which increase cancer risk and stimulate malignant progression. In contrast, cancer-intrinsic or cancer-elicited inflammation can be triggered by cancer-initiating mutations and can contribute to malignant progression through the recruitment and activation of inflammatory cells. Both extrinsic and intrinsic inflammation can result in immunosuppression, thereby providing a preferred background for tumor development. In clinical trials, lifestyle modifications including healthy diet, exercise, alcohol, and smoking cessation have proven effective in ameliorating inflammation and reducing the risk of cancer-related deaths. In addition, consumption of certain anti-inflammatory drugs, including aspirin, can significantly reduce cancer risk, suggesting that common nonsteroidal anti-inflammatory drugs (NSAID) and more specific COX2 inhibitors can be used in cancer prevention. In addition to being examined for their preventative potential, both NSAIDs and more potent anti-inflammatory antibody-based drugs need to be tested for their ability to augment the efficacy of more conventional therapeutic approaches on the basis of tumor resection, radiation, and cytotoxic chemicals. Cancer Prev Res; 9(12); 895-905. ©2016 AACR.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Todoric, J., Antonucci, L., & Karin, M. (2016). Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prevention Research, 9(12), 895–905. https://doi.org/10.1158/1940-6207.capr-16-0209

MLA 9

Todoric, Jelena, et al. “Targeting Inflammation in Cancer Prevention and Therapy.” Cancer Prevention Research, vol. 9, no. 12, 2016, pp. 895–905. https://doi.org/10.1158/1940-6207.capr-16-0209.

Chicago

Todoric, Jelena, Laura Antonucci, and Michael Karin. 2016. “Targeting Inflammation in Cancer Prevention and Therapy.” Cancer Prevention Research 9 (12): 895–905. https://doi.org/10.1158/1940-6207.capr-16-0209.

Harvard

Todoric, J., Antonucci, L. and Karin, M. (2016) ‘Targeting Inflammation in Cancer Prevention and Therapy’, Cancer Prevention Research, 9(12), pp. 895–905. doi:10.1158/1940-6207.capr-16-0209.

IEEE

J. Todoric, L. Antonucci, and M. Karin, “Targeting Inflammation in Cancer Prevention and Therapy,” Cancer Prevention Research, vol. 9, no. 12, pp. 895–905, 2016, doi: 10.1158/1940-6207.capr-16-0209.

BibTeX

@article{todoric2016targeting,
  title     = {{Targeting Inflammation in Cancer Prevention and Therapy}},
  author    = {Todoric, Jelena and Antonucci, Laura and Karin, Michael},
  journal   = {Cancer Prevention Research},
  year      = {2016},
  volume    = {9},
  number    = {12},
  pages     = {895--905},
  doi       = {10.1158/1940-6207.capr-16-0209},
  url       = {https://doi.org/10.1158/1940-6207.capr-16-0209}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20172828
20182929
20194343
20205757
20214949
20224747
20234141
20244646
20252525
20261616

Its field-weighted citation impact is 3.66: it has been cited 3.66 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects

  • inflammation
  • tumor inflammation
  • cancer prevention
  • cancer therapy
  • tumor microenvironment
  • tumor immunosuppression
  • lifestyle modification
  • nonsteroidal anti-inflammatory drugs

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Todoric, J., Antonucci, L., & Karin, M. (2016). Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prevention Research, 9(12), 895–905. https://doi.org/10.1158/1940-6207.capr-16-0209

How many times has this paper been cited?

382 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at PubMed Central.

Who wrote this paper?

Jelena Todoric, Laura Antonucci, Michael Karin.

What is the DOI of this paper?

10.1158/1940-6207.capr-16-0209. The permanent link is https://doi.org/10.1158/1940-6207.capr-16-0209.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.